louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05249751: Copeptin in COVID-19
Official title: Copeptin; A Neuroendocrine Biomarker of COVID-19 Severity
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2022-02-22
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Egyptian patients recruited from Al-Zahraa Hospital, Faculty of Medicine (Girls), Al-Azhar University, Cairo, Egypt

Brief summary: This study aimed to investigate the change in serum level of copeptin, a neuroendocrine biomarker, in differentiation between mild-moderate and severe COVID-19 cases on admission time and to find its diagnostic potential.

Detailed description: This prospective study enrolled 160 individuals with confirmed COVID-19 infection using PCR. They were recruited from Al-Zahraa Hospital, Faculty of Medicine (Girls), Al-Azhar University, Cairo, Egypt, which was specifically designated for the isolation of SARS-CoV-2 positive patients. According to the Egyptian ministry of health and population's (MOHP) recommendations, patients were divided into 80 mild-moderate COVID-19 patients and 80 severe COVID-19 patients. Cases classified as mild-moderate fulfilled the following criteria: fever and respiratory symptoms, CORAD 1-5, and oxygen saturation (SpO2 92 percent), while severe cases met the following criteria: fever and respiratory symptoms, CORAD 4-5, and oxygen saturation (SpO2 92 percent). All participants or their corresponding companions signed a free informed consent form. The study was approved by the research ethics committee of Al-Azhar University's Faculty of Medicine (Girls), Cairo, Egypt, with approval number (202106884), and adhered to the Helsinki Declaration's precepts. Pregnancy, COVID-19 patients with morbid obesity, cancer, or autoimmune disease, and those who took immunomodulators or initiated the COVID-19 treatment programme were excluded. Additionally, patients having a history of recurrent COVID-19 infection were excluded from the study.

Eligibility criteria: Inclusion Criteria:

Adult patients \> 18 years with the positive result of real-time reverse transcriptase-polymerase chain reaction assay (RT-PCR) for SARS-CoV-2 RNA.

Severity stratification is based on the guidance of the Egyptian MOH protocol.

Exclusion Criteria:

Pregnant COVID-19 patients. COVID-19 patients with morbid obesity, malignancy, autoimmune diseases and those who received immunomodulators or began COVID-19 treatment protocol.

Also, patients with a history of recurrent COVID-19 will be excluded.

Primary outcomes:
measure: The role of Copeptin in severity stratification of CoVID-19
timeFrame: By the end of the study (September 2021)
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Al-Zahraa Hospital, Al-Azhar University, Cairo, Egypt
Study officials:
References:
Clinical trial NCT05404451: Comparison of Mulligan Mobilization Technique and Mckenzie Exercises Among Patient With Sacroilliac Joint Dysfunction
Official title: Comparison of Mulligan Mobilization Technique and Mckenzie Exercises Among Patient With Sacroilliac Joint Dysfunction
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Sacroiliac Joint Somatic Dysfunction
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2022-06-03
Enrollment: 58
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Comparison of Mulligan Mobilization Technique and Mckenzie Exercises Among Patient with Sacroilliac Joint Dysfunction

Detailed description: To determine comparison of mulligan mobilization technique and McKenzie exercises in patient with sacroiliac joint dysfunction.

Eligibility criteria: Inclusion Criteria:

* Age between 18 to 65.(29)
* Both male and female and Pain in low back. (17)
* Pain in sacroiliac joint (PSIS) with or without radiating to buttocks.(30)
* With acute/subacute pain within 4-12 weeks of onset and at least three of four clinical tests positive.(14)

Exclusion Criteria:

* Midline pain in back, Lumber stenosis, Lumber radiculopathy, Spondylolisthesis, Disc related pain, Pregnant females with SIJD(29),Any lower limb pathology or hip fracture, Rheumatoid arthritis(17)
* History of any orthopedic surgery, and conditions such as ankylosing spondylitis.(14)
* Spinal leminectomy
* Arthodesis

Primary outcomes:
measure: Mulligan Mobilization Technique
timeFrame: 6 Month
Secondary outcomes:
measure: Mckenzie Exercises
timeFrame: 6 Months
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Social Security hospital Manga road Raiwind.,Chaudary Muhammad Akram research and teaching hospital.
Study officials:
References:
Clinical trial NCT01508351: The Hypotensive Effect of Propofol: an Observational Study
Official title: The Hypotensive Effect of Propofol: an Observational Study of Hypotension With Anesthetic Induction by Propofol in the General Population Under Standard of Care Anesthesia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypotension
Anesthesia
Keywords: Propofol
Induction
Hypotension
General population
Lead sponsor: Milton S. Hershey Medical Center
Sponsor class: OTHER
First posted: 2012-01-11
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hershey Medical Center patients presenting for surgery.

Brief summary: Hypotension is a recognized frequent complication of induction of anesthesia. The intent of this research is to determine the incidence of hypotension in patients receiving anesthetic induction with propofol. This investigation seeks to examine how normal clinical practice or a "real world" understanding of the usual response to propofol affects hemodynamics without isolating or standardizing other variables. The current research concerns hypotension in normal clinical practice where variability exists. This project aims to gather information and data in an attempt to form a foundation upon which each of the other variables affecting blood pressure may be subsequently assessed.


Eligibility criteria: Inclusion Criteria:

* All ASA 1-3 patients who are to receive propofol induction for general anesthesia

Exclusion Criteria:

* Allergy to propofol
* ASA 4 and above

Primary outcomes:
measure: The systolic, diastolic, and mean arterial pressure.
timeFrame: Within first 20 minutes after anesthesia induction
Secondary outcomes:
Other outcomes:
Locations:
city: Hershey
country: United States
facility: Milton S. Hershey Medical Center
state: Pennsylvania
Study officials:
References:
Clinical trial NCT00242151: Prevalence of Delirium in Patients Undergoing Cardiac Surgery
Official title: Prevalence of Delirium in Patients Undergoing Cardiac Surgery
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Heart Disease
Keywords: Delirium, Confusion, Cardiac Surgery, Organic Brain Injury, Diffusion Weighted Magnetic Resonance Imaging (DW-MRI)
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2005-10-19
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: PROSPECTIVE

Brief summary: The objective of this study is to determine prevalence of postoperative delirium and confusion in patients undergoing cardiac surgery. This proposal is a pilot study designed to evaluate effect of cardiac surgery on prevalence of delirium and confusion.

The primary aim is to evaluate prevalence of delirium and confusion in patients undergoing cardiac surgery and to determine risk factors for this condition.

A secondary aim is to evaluate organic brain injury by early postoperative diffusion weighted magnetic resonance imaging (DW-MRI) in patients who develop delirium and confusion.

The hypothesis to be tested is that patients with postoperative delirium and confusion have high incidence of organic brain injury as detected by DW-MRI.


Eligibility criteria: Inclusion criteria:

* All patients undergoing cardiac surgery in our institute in 2 year period
* Signed informed consent

Exclusion criteria:

* Past history of transient ischemic attacks, stroke, symptomatic carotid artery disease.
* Past history of psychiatric disorders
* History of alcohol and drug abuse
* History of severe kidney or liver disease (creatinine \>2.5mg/dL and bilirubin \> 2mg/dL)
* Known contraindications to MRI

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Toronto General Hospital, University Health Network
state: Ontario
Study officials:
affiliation: Toronto General Hospital, University Health Network
name: Rita Katznelson, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06395077: Diagnostic Efficiency of Low-dose Cone-beam Computed Tomography in Post-graft Evaluation.
Official title: Diagnostic Efficiency of Low-dose Cone-beam Computed Tomography in Post-graft Evaluation of Swedish Paediatric Patients With Alveolar Clefts
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Alveolar Cleft
Keywords: CBCT
Low-dose
Alveolar cleft
Lead sponsor: Malmö University
Sponsor class: OTHER
Collaborators: name: Region Skane
First posted: 2024-05-01
Enrollment: 11
Sex: ALL
Minimum age (years): 7
Maximum age (years): 14
Standard ages: CHILD
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with oral facial clefts who had undergone alveoalar bone grafting. Healing control after 6 months.

Brief summary: Evaluation of a Low-dose exposure CBCT protocol for post-graft evaluation of treatment of cleft patients

Detailed description: The patient underwent two CBCT examinations (Accuitomo 170; J Morita Corp., Kyoto, Japan): one examination followed the clinical standard-dose protocol (exposure settings: 90 kV, 5 mA, and 9.4 s), and one, the low-dose protocol (90 kV, 2 mA, 9.4 s). The field of view (FOV) was 6.0 cm x 6.0 cm, the rotation mode was 180 degrees, and voxel size was 0.125 mm. Volume was reconstructed in slices of 1-mm thickness and interval. The dose area products (DAP) were 423 mGy cm2 for the clinical, standard-dose protocol and 172 mGy cm2 for the low-dose protocol.

The aim was to establish if a low-dose protocol could provide diagnostically acceptable image quality for assessing bone healing after alveolar bone grafting.

Eligibility criteria: Inclusion Criteria:

* patients with oral facial clefts who had undergone alveoalar bone grafting. Healing control after 6 months.

Exclusion Criteria:

-

Primary outcomes:
measure: Evaluation of post grafting in patients with clefts.
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Malmo
country: Sweden
facility: Kristina Hellen-Halme
Study officials:
affiliation: Malmo university
name: Kristina Hellén-Halme
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06933277: Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients
Official title: Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone (SVd) for the Treatment of Multiple Myeloma Patients
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Multiple Myeloma
Keywords: selinexor
bortezomib
dexamethasone
Lead sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Sponsor class: OTHER
First posted: 2025-04-18
Enrollment: 159
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: this study will include patients who will start SVD treatment during the study enrolment period or who received at least one dose of the treatment according to AIFA authorization before the study inclusion date.

Brief summary: This is an observational study aiming at collecting efficacy and safety data on the use of SVd outside clinical trials, for the treatment of adult patients with MM who have received 1-3 prior line of therapy.

A minimum of 159 patients is required. Overall study duration is estimated in 36 months.

Detailed description: This is a non-interventional, national, multicenter prospective and retrospective observational study aiming at collecting efficacy and safety data on the use of SVd outside clinical trials, for the treatment of adult patients with MM who have received 1-3 prior line of therapy.

All the sites participating in the study are using SVd in clinical practice. According to sample size calculation, a minimum of 159 patients is required.

Overall study duration is estimated in 36 months: 24 months on enrolment and at least 12 months of observation.

Eligibility criteria: Inclusion Criteria:

* Age equal to or greater than 18 years old at the time of SVd initiation
* Signed informed consent (if applicable).
* Diagnosis of symptomatic MM, as defined by the International Myeloma Working Group (IMWG) criteria.
* Relapse after one to three lines of therapy.
* Treatment with SVd, (i.e., having already received at least one dose) at the time the combination has entered clinical practice in Italy (AIFA authorization)
* Prior treatment with and refractoriness to lenalidomide.

Exclusion Criteria:

- Previous exposure to selinexor.

Primary outcomes:
measure: SdV therapy effectiveness in terms of Progression Free Survival
timeFrame: at 12 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: UOC di Ematologia Policlinico S.Orsola AOU di Bologna
name: Elena Zamagni
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05661253: Modified Versus Conventional Serratus Anterior Plane Block
Official title: Ultrasound Guided Modified Versus Conventional Serratus Anterior Plane Block as a Preemptive Analgesia for Unilateral Video-Assisted Thoracoscopic Surgery
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Postoperative Pain, Acute
Lead sponsor: Zagazig University
Sponsor class: OTHER_GOV
First posted: 2022-12-22
Enrollment: 99
Sex: ALL
Minimum age (years): 21
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: comparing preemptive analgesia with ultrasound guided modified serratus anterior plane block versus ultrasound guided serratus anterior plane block

Detailed description: comparing the quality of postoperative analgesia and opioid consumption in patients undergoing Video-Assisted Thoracoscopic Surgery when using preemptive analgesia with ultrasound guided modified serratus anterior plane block versus ultrasound guided serratus anterior plane block

Eligibility criteria: Inclusion Criteria:

* Patient consent.
* both sex.
* Age: 21-70 years old.
* BMI: 18- 30 kg/m2
* ASA: I and II.
* Scheduled for elective unilateral Video-Assisted thoracoscopy under general anesthesia.

Exclusion Criteria:

* History of allergy to the local anesthesia agents used in this study,
* Skin lesion at needle insertion site,
* Those receiving anticoagulant therapy or having bleeding disorders
* Patients with history of chronic pain and taking analgesics,
* Patients with sepsis and Significant cardiac, liver or renal diseases
* Uncooperative patients or with psychiatric disorders.

Primary outcomes:
measure: tramadol consumption
timeFrame: at 24 hours postoperative
Secondary outcomes:
measure: Time of performance
timeFrame: from ultrasound probe positioning till the end of the block procedure
measure: Time to first dose of rescue analgesia
timeFrame: during the first postoperative 24 hours
measure: Patient satisfaction
timeFrame: at 24 hous post operative
Other outcomes:
Locations:
city: Zagazig
country: Egypt
facility: Heba M Fathi
Study officials:
affiliation: faculty of human medicine ,zagazig university
name: Heba M Fathi
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06022653: Asan Aorta and Peripheral Registry
Official title: Evaluation of Patients Underwent Revascularization of Aorta or Peripheral Artery at the Peripheral Vascular Disease Center, Asan Medical Center; A Single Center, Retrospective/Prospective Observational Study.
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Aorta Disease
Peripheral Artery Disease
Keywords: Revascularization of Aorta or Peripheral artery
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
First posted: 2023-09-05
Enrollment: 6000
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients underwent Revascularization of Aorta or Peripheral artery from 2011 at the Peripheral Vascular Disease Center, Asan Medical Center

Brief summary: The purpose of this study is to evaluate the clinical results of patients who received revascularization of the aorta and peripheral artery at Asan Medical Center.

Detailed description: This study is a single center retrospective and prospective observational study to evaluate the clinical results of patients who received revascularization of the aorta and peripheral artery at asan medical center.

Data will be collected on approximately 6,000 subjects in asan medical center. Individuals will be followed up at 1, 6, and 12 months, 3, 5years up to 10 years by telephone call or hospital visit.

Data collected during all follow-up visits will include a composite of major adverse limb events, or death from any cause.

Eligibility criteria: Inclusion Criteria:

* Patients underwent Revascularization of Aorta or Peripheral artery from 2011 at the Peripheral Vascular Disease Center, Asan Medical Center
* Patients with aortic and peripheral artery disease are defined as:

Thoacic aorta disease/ abdominal aorta disease

1. Aneurysm
2. Aortic dissection
3. Penetrating aortic ulcer

Peripheral artery occlusive disease

1. Chronic Limb-Threatening Ischemia
2. Claudication
3. Acute limb ischemia

Exclusion Criteria:

* For prospective cohort, not agreeing to participate with written informed consent form

Primary outcomes:
measure: Rate of death from any cause
timeFrame: 10years
measure: Rate of major Adverse Limb Events
timeFrame: 10years
Secondary outcomes:
measure: Rate of death from all cause including cardiovascular death
timeFrame: 10years
measure: Rate of stroke
timeFrame: 10years
measure: Rate of myocardial Infarction
timeFrame: 10years
measure: Rate of vascular complication
timeFrame: 10years
measure: Rate of bleeding
timeFrame: 10years
measure: Success of the procedure
timeFrame: 10years
measure: Rate of limb amputation
timeFrame: 10years
measure: Rate of reintervention of aorta , reintervention of index limb or non-index limb
timeFrame: 10years
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
affiliation: Asan Medical Center
name: Seung-Whan Lee
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06303453: Comparative Effects of Balance and Resisted Training in Diabetic Peripheral Neuropathy.
Official title: Comparative Effects of Balance and Resisted Training on Pain and Balance In Patients With Diabetic Peripheral Neuropathy.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetic Peripheral Neuropathy
Keywords: Diabetic Peripheral Neuropathy
Balance Training
Resisted Training
Pain Management
Rehabilitation Exercises
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2024-03-12
Enrollment: 58
Sex: ALL
Minimum age (years): 40
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to determine comparative effects of balance and resisted training on pain and balance in patients with daibetic peripheral neuropathy.

Detailed description: This randomized clinical trial will be conducted at Mumtaz Bakhtawar Hospital in 7 months after the approval of synopsis. The sample size for this trial will be 58 patients with DPN. Participants those meet inclusion criteria will be randomly allocated into two groups using online randomization tool, 29 participants will be assigned to Group A which will receive Balance training exercises for 35 minutes and Group B will receive Resistance Training exercises for 45 minutes. Each participant will receive intervention for 3 alternate days per week for 8 weeks.

The Michigan neuropathy screening instrument will be used for the assessment of DPN symptoms scores at baseline. Balance will be evaluated using the De Morton mobility index (DEMMI) test, while painDIRECT tool will be utilized to measure pain. The data will be entered and analyzed using SPSS version 24 for windows software.

Eligibility criteria: Inclusion Criteria:

1. Patients diagnosed with DNP with score ≥ 2.5 on Michigan neuropathy screening instrument of both genders.
2. Age between 40 to 65 years.
3. Patients having the minimum history of diabetes is 7 years.
4. History of mild to moderate neuropathy . The patients ability to do resistance and aerobic exercises.

Exclusion Criteria:

1. History of taking anti-inflammatory drugs.
2. History of recent surgical operations of joints in lower extremities.
3. Patients suffering from musculoskeletal disorders such as rheumatoid arthritis and myopathy.
4. Patients having any disability, fracture, or dislocation of at least six months before the study.

Primary outcomes:
measure: Michigan neuropathy screening instrument
timeFrame: 8th week
measure: De Morton mobility index test
timeFrame: 8th week
measure: PainDETECT Tool
timeFrame: 8th week
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Riphah International University
state: Punjab
Study officials:
affiliation: Riphah International University
name: Muhammad Kashif, PhD-PT
role: STUDY_CHAIR
References: